Home > Insider Trading > Filing (0001562180-20-004472)

Filing Details

Accession Number:: 0001562180-20-004472
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-12 21:51:40
Reporting Period:: 2020-06-12

Accepted Time:: 2020-06-12 21:51:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1785732	Elyse Stock	C/O Biohaven Pharmaceuticals, Inc., 215 Church Street New Haven CT 06510	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2020-06-12	20,716	$20.79	22,560	No	4	M	Direct
Common Shares	Acquisiton	2020-06-12	16,250	$32.42	38,810	No	4	M	Direct
Common Shares	Disposition	2020-06-12	4,351	$63.02	34,459	No	4	S	Direct
Common Shares	Disposition	2020-06-12	5,300	$64.05	29,159	No	4	S	Direct
Common Shares	Disposition	2020-06-12	15,925	$64.89	13,234	No	4	S	Direct
Common Shares	Disposition	2020-06-12	11,390	$65.80	1,844	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2020-06-12	16,250	$0.00	16,250	$32.42
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2020-06-12	20,716	$0.00	20,716	$20.79

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
48,750		2028-11-20	No	4	M	Direct
21,896		2027-12-06	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	937	Indirect	By Spouse

Footnotes

These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.40 - $63.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.40 - $64.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.40 - $65.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.40 - $66.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The option vests in 4 equal installments on the first, second, third and fourth anniversaries of November 20, 2018, in each case subject to the reporting person's continuing service as of each applicable vesting date.
The option became exercisable as to 10,653 of these shares on December 7, 2018, with the remainder vesting in 3 equal installments on December 7, 2019, December 7, 2020 and December 7, 2021, subject to the reporting person's continuing service as of each applicable vesting date.